Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects
This study has been completed.
Information provided by:
First received: April 23, 2007
Last updated: July 22, 2011
Last verified: July 2011
The primary objective is to determine the safety and tolerability of the new IV formulation versus the current formulation of MOA-728 focusing on the theoretical potential for infusion-related and formulation-related complications.
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
||A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Comparison With the Current Formulation in Healthy Subjects
Primary Outcome Measures:
- IV site tolerability and urinary zinc excretion
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- A signed and dated informed consent form.
- Men or nonlactating and nonpregnant women, aged 18 to 80 years, inclusive.
- Women of nonchildbearing potential (WONCBP) must be surgically sterile (hysterectomy, oophorectomy, and/or tubal ligation) or postmenopausal for ³1 year.
- Women of childbearing potential (WOCBP) must be using an acceptable nonhormonal method of contraception (intrauterine device [IUD], diaphragm, or condom with spermicidal jelly or foam, abstinence) for a period of at least 1 month before and after dose administration.
- All women must have a negative pregnancy test result within 48 hours before the start of the first test article administration.
- Body mass index in the range of 18 to 32 kg/m² and body weight ≥50 kg.
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG).
- Subjects aged 65 to 80 years should be healthy, but may be enrolled with a chronic illness, if such illness is well controlled and does not interfere with the primary objective of the study. Certain concomitant medications will be allowed for the treatment of these conditions and are listed in the Concomitant Treatment section.
- Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to abstain from smoking from 48 hours before and throughout the inpatient stay.
- Have a high probability for compliance with and completion the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00464802
|Phoenix, Arizona, United States, 85044 |
No publications provided
||Jeff Cohn, Salix Pharmaceuticals
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 23, 2007
||July 22, 2011
||United States: Food and Drug Administration
Keywords provided by Salix Pharmaceuticals:
ClinicalTrials.gov processed this record on March 10, 2014